- Home
- KNSA vs CSQ Comparison
KNSA vs CSQ Comparison
Compare KNSA & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$41.52
Company Overview
Basic Information| Metric | KNSA | CSQ |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | CSQ |
|---|---|---|
| Price | $41.52 | $18.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | ★ 345.4K | 220.3K |
| Earning Date | 10-28-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | N/A |
| Revenue This Year | $62.63 | N/A |
| Revenue Next Year | $29.93 | N/A |
| P/E Ratio | $89.09 | ★ N/A |
| Revenue Growth | ★ 55.68 | N/A |
| 52 Week Low | $17.82 | $12.50 |
| 52 Week High | $42.98 | $16.45 |
Technical Indicators
Market Signals| Indicator | KNSA | CSQ |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 48.30 |
| Support Level | $40.33 | $18.75 |
| Resistance Level | $42.32 | $19.44 |
| Average True Range (ATR) | 1.45 | 0.24 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 56.68 | 55.56 |
Price Performance
Historical Comparison KNSA
CSQ
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.